Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.39 |
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18607029 | 0.86 | PIN1 (0.36) | PIN1KMT2ALMNAGAAEGFR | |
| SCHEMBL18607370 | 0.83 | PIN1 (0.34) | PIN1EGFRALDH1A1 | |
| SCHEMBL26324590 | 0.82 | LRRK2 (0.39) | KMT2ALMNAEGFRMAPTHPGD | |
| SCHEMBL29597402 | 0.82 | KMT2A (0.47) | KMT2ALMNAGAAEGFRABCG2 | |
| SCHEMBL26324772 | 0.81 | EGFR (0.40) | KMT2ALMNAEGFRMAPTHPGD | |
| SCHEMBL22509157 | 0.81 | EGFR (0.40) | KMT2ALMNAGAAEGFRFGFR4 | |
| SCHEMBL30705257 | 0.81 | EGFR (0.40) | KMT2ALMNAGAAEGFRFGFR4 | |
| SCHEMBL22507833 | 0.81 | EGFR (0.43) | KMT2ALMNAEGFRMAPTHPGD | |
| SCHEMBL20987207 | 0.81 | LRRK2 (0.48) | LRRK2 | |
| SCHEMBL30040344 | 0.81 | LRRK2 (0.48) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258344-B2 | Azaaromatic amide derivatives for the treatment of cancer | SHENZHEN FORWARD PHARMACEUTICALS CO., LTD. (CN) | 2025-03-25 | — | — | US | disclosed |
| CN-115836064-B | Triazine derivative with EGFR (epidermal growth factor receptor) inhibition activity as well as preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-113179640-B | Nitrogen-containing polycyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240109885-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| CN-117430600-A | Selective EGFR inhibitor, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-4257584-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-20230293535-A1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| CN-115867539-A | 2, 3-dihydro-1H-pyrrolo [3,2-b ] pyridine derivatives, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115836064-A | Triazine derivative with EGFR (epidermal growth factor receptor) inhibitory activity and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20220177473-A1 | AZAAROMATIC AMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | SHENZHEN FORWARD PHARMACEUTICALS CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| EP-3345906-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Wuxi Shuangliang Biotechnology Co., Ltd. (CN) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017035753-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | 无锡双良生物科技有限公司 | 2017-03-09 | — | — | WO | disclosed |
| US-20170008889-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2017-01-12 | — | — | US | disclosed |
| US-20170008889-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2017-01-12 | — | — | US | disclosed |
| US-20170008889-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2017-01-12 | — | — | US | disclosed |
| EP-3112364-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015188747-A1 | PHENYL-SUBSTITUTED TRIAZINE COMPOUND SERVING AS EGFR INHIBITOR AND APPLICATIONS THEREOF | 南京圣和药业股份有限公司 | 2015-12-17 | — | — | WO | disclosed |
| WO-2015127872-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | 上海海雁医药科技有限公司 | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008889-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | ERBB2, EGFR, ERBB3 | PIN1 799/4885KMT2A 2095/4885LMNA 4641/4885 |
| US-20240109885-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, WEE2, EGFR | PIN1 150/4885KMT2A 4234/4885LMNA 2682/4885 |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | ERBB2, EGFR, ERBB3 | PIN1 3727/4885KMT2A 2918/4885LMNA 3618/4885 |
| US-20220177473-A1 | AZAAROMATIC AMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | ERBB4, EGFR, ERBB2 | PIN1 1294/4885KMT2A 1184/4885LMNA 4819/4885 |
| US-12258344-B2 | Azaaromatic amide derivatives for the treatment of cancer | ERBB4, EGFR, ERBB2 | PIN1 1294/4885KMT2A 1184/4885LMNA 4819/4885 |
| US-20230293535-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | PIN1 988/4885KMT2A 1314/4885LMNA 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.